Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 7 8 9 10 presentations: 1 to 25 of 248
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Inhibiting immune checkpoints
Mary L. Disis
University of Washington, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory T cells
Dario A. Vignali
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory myeloid cells
Dmitry I. Gabrilovich
The Wistar Institute, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Galectins and immune response in cancer
Gabriel A. Rabinovich
Instituto de BiologĂ­a y Medicina Experimental, CONICET, Ciudad de Buenos Aires, Argentina
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Chairperson
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Leisha A Emens
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Issues faced by industry in developing safe and effective combination immunotherapies
Ira Mellman
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Statistical challenges in designing combination immunotherapy clinical trials
Katy Simonsen
Bristol-Myers Squibb Co., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
FDA's point of view on trial designs for accelerating combination immunotherapies across multiple tumor types
Tatiana Prowell
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Harnessing the Power of Mouse Models for Cancer Immunology Research
Introduction
Lisa M. Coussens
OHSU Knight Cancer Institute, Portland, OR, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Harnessing the Power of Mouse Models for Cancer Immunology Research
Lymphatic vessels, inflammation, and Immunity in solid tumors
Amanda Waite Lund
Oregon Health & Science University, Portland, OR, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Harnessing the Power of Mouse Models for Cancer Immunology Research
Identifying myeloid-driven biologies
Brian Ruffell
H. Lee Moffitt Cancer Center, Tampa, FL, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Harnessing the Power of Mouse Models for Cancer Immunology Research
Engineering T cells for pancreas cancer
Sunil R. Hingorani
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Harnessing the Power of Mouse Models for Cancer Immunology Research
Translating cancer neoantigens
Gerald P. Linette
Washington University, St. Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Deciphering cancer genome evolution and intra-tumor heterogeneity: The TRACERx Analysis Pipeline
Gareth A Wilson
The Francis Crick Institute, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Detecting mutational signatures in heterogeneous tumors
Ludmil B Alexandrov
Los Alamos National Laboratory, Los Alamos, NM, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Neutral evolution in cancer: Making sense of intra-tumor heterogeneity
Andrea Sottoriva
The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Inferring the clonaldynamics underlying histologically transformed and treatment resistant follicular lymphomas
Fong Chun Chan
BC Cancer Agency Vancouver BC, Vancouver, BC, Canada
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
<< first | < prev page: of 10 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 7 8 9 10 presentations: 1 to 25 of 248